QUALITY OF LIFE IMPROVEMENTS IN PSORIASIS WITH SECUKINUMAB IN A DIFFICULT TO TREAT POPULATION OF ANTI-TNF ALPHA FAILURE PATIENTS FROM THE UK AND REPUBLIC OF IRELAND
Author(s)
Warren R1, Finlay A2, Barker J3, Burden D4, Williams R5, Armendariz Y6, Halliday A7, Griffiths CE8
1University of Manchester, Manchester, UK, 2Cardiff University, Cardiff, UK, 3King's Colledge London, London, UK, 4Royal Infirmary of Edinburgh, Edinburgh, UK, 5Novartis Pharmaceuticals UK Ltd, Frimley, UK, 6Novartis Pharmaceuticals UK td, Frimley, UK, 7Novartis Pharmaceuticals UK Ltd, Camberley, Surrey, UK, 8The University of Manchester, Manchester, Switzerland
OBJECTIVES: Psoriasis can have a large impact on quality of life (QoL). Secukinumab, a fully human anti–interleukin-17A monoclonal antibody is licensed for the treatment of plaque psoriasis in adults who are candidates for systemic therapy. QoL results are presented from an open-label, non-comparator study that investigated the safety and efficacy of secukinumab in patients who previously failed anti-tumour necrosis factor (TNF) α biologic therapy. METHODS: RESULTS: Results are presented for 118 patients on the dose of secukinumab licensed for psoriasis (300mg). At baseline, mean DLQI was 20.2 (SD=6.03). By week 16 this improved to 4.2 (SD=4.97). Improvements were maintained amongst patients remaining in the study; 4.2 (SD=5.90) at week 48 and 3.7 (SD=5.41) at week 72. Baseline EQ-5D-5L mean visual analogue score (VAS; range 0-100, lower scores reflecting worse QoL) was 54.9 (SD=24.84). By week 16 this improved to 76.3 (SD=21.58). Improvements were maintained amongst patients remaining in the study; 77.7 (SD=21.60) at week 48 and 78.2 (SD=19.80) at week 72. EQ-5D domains impacting the largest proportion of patients at baseline were pain/discomfort (90%; 106/118 patients) and anxiety/depression (77%; 91/118). By weeks 16, 48 and 72 respectively, fewer patients were reporting pain/discomfort; 53% (63/118), 43% (46/107) and 52% (43/83) and anxiety/depression; 38% (45/118), 36% (39/107) and 37% (31/83). CONCLUSIONS: These results demonstrate that secukinumab 300mg provides sustained QoL improvements even in a difficult to treat anti-TNFa failure population of psoriasis patients.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PSS7
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Sensory System Disorders